| Study | Reason for exclusion |
|---|---|
| Aberg 2017 | Confounding factor: protease inhibitors of treating HIV |
| CTRI201305003686 2013 | Dose is 2‐4 mg/day pitavastatin one/two Pitavastatin 2 mg tablets per day |
| CTRI201307003842 2013 | Washout period unclear |
| CTRI201309004003 2013 | Washout period unclear |
| Horiuchi 2010 | Combined different statins |
| Huang 2016 | Trial excluded because dose was 1‐2 mg/day and lipids had median percentage change from baseline |
| Hyogo 2011 | Run‐in washout period not reported |
| Inami 2007 | Some participants may have had at least 3‐week washout period but others only 2 weeks. |
| Jing 2008 | Dose unclear |
| Joshi 2017 | Confounding factor: protease inhibitors of treating HIV |
| JPRN JMA IIA00056 2011 | Dose is 1‐4 mg/day dose range |
| JPRN UMIN000000685 2007 | Participants may be receiving lipid altering agents at baseline no washout period reported |
| JPRN UMIN000001600 2009 | Dose is 1 or 2 mg/day dose not specific |
| JPRN UMIN000002507 2009 | Participants were receiving lipid altering agents at baseline |
| JPRN UMIN000002680 2009 | Patients received cholesterol lowering drugs at baseline |
| JPRN UMIN000003554 2010 | no 3‐12 week lipid data 12‐16 weeks |
| JPRN UMIN000003628 2010 | Dose is 1‐4 mg/day dose range |
| JPRN UMIN000005489 2011 | Participants may be receiving lipid altering agents at baseline no washout period reported |
| JPRN UMIN000005501 2011 | Participants may be receiving lipid altering agents at baseline no washout period reported |
| JPRN UMIN000007130 2012 | Participants may be receiving non statin lipid altering agents at baseline no washout period reported |
| JPRN UMIN000007695 2012 | Participants may be receiving non statin lipid altering agents at baseline no washout period reported |
| JPRN UMIN000009241 2012 | Participants may be receiving lipid altering agents at baseline no washout period reported |
| JPRN UMIN000013384 2014 | Participants are receiving a statin excluding pitavastatin at baseline |
| JPRN UMIN000019020 2015 | Participants may be receiving lipid altering agents at baseline no washout period reported |
| Kawashiri 2008 | Confounding factor in 5 of the 19 subjects |
| Matsubara 2012 | Confounding factor |
| Minai 2008 | Trial period reported as 8 weeks or more |
| Muto 2013 | Some participants received lipid‐lowering agents at baseline |
| Nakamura 2006 | Subjects may be receiving lipid altering agents at baseline |
| Nakaya 2001 | Baseline washout period too short |
| NCT02670434 2016 | Terminated The study was aborted and the investigators provided no data |
| NCT02799758 2016 | Terminated The study was aborted and the investigators provided no data |
| Nishiguchi 2018 | Median percent change from baseline |
| Nomura 2008 | Some participants may have had at least a 3‐week washout period but others only 2 weeks. |
| Nozue 2015 | Median percent change from baseline |
| Rui 2014 | Article not available from any library |
| Watanabe 2015 | Dose unclear |
| Wongprikorn 2016 | Confounding factor |
| Yagi 2011 | Some participants were treated for 12 weeks while some were treated for more than 12 weeks. |
| Yao 2016 | Article retracted |
| Zhu 2010 | Washout period of all previous lipid‐lowering drugs not clear |
HIV: Human Immunodeficiency Virus